Goodwin Procter LLP advised Vascular Biogenics Ltd. on the deal. Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT) announced the closing of its underwritten public offering...
Goodwin Procter LLP advised Vascular Biogenics Ltd. on the deal. Vascular Biogenics Ltd. (“VBL Therapeutics” or the “Company”) (NASDAQ: VBLT) announced the closing of its underwritten public offering...